$43.01
9.69%
Nasdaq, Jun 06, 10:13 pm CET
ISIN
US8036071004
Symbol
SRPT

Sarepta Therapeutics, Inc. Stock price

$43.01
-3.74 8.00% 1M
-85.16 66.44% 6M
-78.58 64.63% YTD
-74.43 63.38% 1Y
-116.67 73.06% 5Y
+16.82 64.19% 10Y
+28.55 197.44% 20Y
Nasdaq, Closing price Fri, Jun 06 2025
+3.80 9.69%
ISIN
US8036071004
Symbol
SRPT
Sector
Industry

Key metrics

Market capitalization $4.23b
Enterprise Value $4.84b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.17
P/S ratio (TTM) P/S ratio 1.89
P/B ratio (TTM) P/B ratio 3.70
Revenue growth (TTM) Revenue growth 59.16%
Revenue (TTM) Revenue $2.23b
EBIT (operating result TTM) EBIT $-117.21m
Free Cash Flow (TTM) Free Cash Flow $-697.55m
Cash position $522.76m
EPS (TTM) EPS $-2.55
P/E forward negative
P/S forward 1.64
EV/Sales forward 1.88
Short interest 10.52%
Show more

Is Sarepta Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,823 stocks worldwide.

Sarepta Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

27 Analysts have issued a Sarepta Therapeutics, Inc. forecast:

23x Buy
85%
4x Hold
15%

Analyst Opinions

27 Analysts have issued a Sarepta Therapeutics, Inc. forecast:

Buy
85%
Hold
15%

Financial data from Sarepta Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
2,233 2,233
59% 59%
100%
- Direct Costs 406 406
145% 145%
18%
1,827 1,827
48% 48%
82%
- Selling and Administrative Expenses 565 565
13% 13%
25%
- Research and Development Expense 1,378 1,378
66% 66%
62%
-115 -115
24% 24%
-5%
- Depreciation and Amortization 2.41 2.41
23% 23%
0%
EBIT (Operating Income) EBIT -117 -117
24% 24%
-5%
Net Profit -248 -248
1,564% 1,564%
-11%

In millions USD.

Don't miss a Thing! We will send you all news about Sarepta Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Sarepta Therapeutics, Inc. Stock News

Neutral
Business Wire
5 days ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the rAAVrh74 viral vector used in the investigational gene therapy SRP-9003 (bidridistrogene xeboparvovec) for the treatment of limb-girdle muscular dystrophy type 2E/R4, has been granted platform technology designation by the U.S. Food & ...
Neutral
Business Wire
19 days ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, shared the following update related to ELEVIDYS (delandistrogene moxeparvovec-rokl), the only approved gene therapy for patients with Duchenne muscular dystrophy. We have received feedback from the Medicines & Healthcare products Regulatory Agency (MHRA) in th...
Neutral
Business Wire
24 days ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported new results from Study 9001-103. Also known as ENDEAVOR, Study 9001-103 is a multi-cohort study of ELEVIDYS (delandistrogene moxeparvovec-rokl) for the treatment of Duchenne muscular dystrophy. Treatment with ELEVIDYS in the ENDEAVOR participant...
More Sarepta Therapeutics, Inc. News

Company Profile

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Head office United States
CEO Douglas Ingram
Employees 1,372
Founded 1980
Website www.sarepta.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today